Protocoles SEP

Créé par la Clinique Neuro-Outaouais

Contact Us

Bienvenue sur Protocoles SEP

Protocoles SEP est un référentiel concis et à jour d’information sur les traitements de la sclérose en plaques (SEP) qui rassemble, sous un même domaine, des études cliniques, des monographies de produit, les exigences provinciales de remboursement des médicaments et des protocoles de traitement.

L’objectif de Protocoles SEP est double : aider les médecins à trouver le plus rapidement possible des réponses à leurs questions sur les traitements de la SEP, et offrir une plateforme commune pour partager, pour la première fois en ligne, des protocoles de traitement spécifiques à la SEP. À cette fin, nous invitons les médecins à nous contacter et, s’ils le souhaitent, à partager leurs protocoles SEP, afin d’accroître l’accessibilité et la qualité de l’information sur les traitements.

MS Protocols

Created by Clinique Neuro-Outaouais

Welcome

MS Protocols is a concise repository of up-to-date MS treatment information which assembles clinical studies, product monographs, provincial drug coverage requirements, and treatment protocols under a single domain.

MS Protocols’ aim is twofold: to help doctors find the answers to MS treatment questions as rapidly as possible, and to serve as a common platform to share, for the first time online, treatment specific MS protocols. To that end, we encourage physicians to contact us, and, if they so wish, to share their MS Protocols so as to further the availability and quality of MS treatment information.

Thérapies pour la SEP

Aubagio

Teriflunomide

02416328

Avonex / Plegridy

Interferon Beta 1a

Avonex:02269201
Plegridy:02444399

Betaseron / Extavia

Interferon Beta 1a

Betaseron: 02169649
Extavia:02337819

Copaxone

Glatiramer Acetate

20mg/ml: 02245619
40mg/ml:02456915

Fampyra / Ampyra

A-aminopyridine

02379910

Gilenya

Fingolimod

02365480

Glatect

Glatiramer acetate

02460661

Kesimpta

ofatumumab

02511355

Lemtrada

Alemtuzumab

02418320

Mavenclad

Cladribine

02470179

Mayzent

Siponimod

02496437, 02496429

Ocrevus

Ocrelizumab

02467224

Rebif

Interferon Beta 1a

02318261

Tecfidera

Dimethyl Fumarate

02404508

Tysabri

Natalizumab

02286386

Zeposia

ozanimod

0250599

PML Management

Progressive Multifocal Leukoencephalopathy (PML) is an opportunistic infection whose classic histopathological triad of demyelination, bizarre astrocytes and oligodendrogial nuclear inclusion was first described in 1958. It was in 1971 that the polyoma virus, John Cunningham (JC), was discovered to be the cause of the infection. Click below to learn more.

Learn More

Pregnancy

It was not that long ago that neurologists recommended to patients to avoid getting pregnant for fear of worsening the disease course. We can now confidently affirm that multiple sclerosis does not affect pregnancy or the fetus. The risk of developing MS in the offspring is proportional to the genetic loading as pregnancy affects the course of the disease.

Learn More

Vaccination

Vaccination is an important preventative measure for our MS patients.There is much debate whether a given therapy is immunosuppressive or not. In the author’s view, any therapy that can lead to any or all of the following is an immunosuppressive agent such as causing sustained lymphopenia and/or neutropenia and reducing the immune system.

Learn More